Adjuvant Endocrine Therapy for Hormone-positive Breast Cancer, Focusing on Ovarian Suppression and Extended Treatment: An Update
| Autor: | Shazza Rehman, Sue Hignett, Mohamed Salhab, Daniel Glassman, Richard Linforth |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Selective Estrogen Receptor Modulators
Oncology medicine.medical_specialty Neoplasms Hormone-Dependent Time Factors Antineoplastic Agents Hormonal Breast Neoplasms Ovary Drug Administration Schedule 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Breast cancer Exemestane Risk Factors Internal medicine Humans Medicine Endocrine system 030212 general & internal medicine business.industry Patient Selection Letrozole medicine.disease Treatment Outcome medicine.anatomical_structure Receptors Estrogen chemistry Chemotherapy Adjuvant Selective estrogen receptor modulator 030220 oncology & carcinogenesis Female business Tamoxifen Signal Transduction Hormone medicine.drug |
| Zdroj: | Anticancer Research. 37 |
| DOI: | 10.21873/anticanres.11959 |
| Popis: | The benefits of five years of adjuvant endocrine therapy for oestrogen receptor (ER)-positive early breast cancer are well established. However, recent evidence suggests that extended endocrine treatment and ovarian suppression in selected groups of patients have significant advantages. In this article, we review the current evidence for adjuvant endocrine therapy in breast cancer with focus on extended adjuvant endocrine therapy and ovarian suppression, and also highlight the advantages and disadvantages of these therapeutic strategies. A literature search was performed through PubMed, Medline, and Cochrane using the following search terms: Endocrine therapy, Tamoxifen, Anastrazole, Ovarian Suppression, Exemestane, Letrozole and STS Inhibitors. All available evidence for adjuvant endocrine therapy was reviewed and summarised to assess the current guidance and the progress of the management of patients with ER-positive breast cancer. Extended endocrine therapy should be tailored according to patient needs dictated by their individual risk factors, molecular type of breast cancer, menopausal status, comorbidities, life style and risk of recurrence. Clinicians ought to discuss with patients the pros and cons of different adjuvant endocrine therapy approaches and highlight the potential side effects and toxicity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|